首页> 美国卫生研究院文献>Springer Open Choice >Characterising microbial protein test substances and establishing their equivalence with plant-produced proteins for use in risk assessments of transgenic crops
【2h】

Characterising microbial protein test substances and establishing their equivalence with plant-produced proteins for use in risk assessments of transgenic crops

机译:鉴定微生物蛋白测试物质并确定其与植物产生的蛋白的等效性以用于转基因作物的风险评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Most commercial transgenic crops are genetically engineered to produce new proteins. Studies to assess the risks to human and animal health, and to the environment, from the use of these crops require grams of the transgenic proteins. It is often extremely difficult to produce sufficient purified transgenic protein from the crop. Nevertheless, ample protein of acceptable purity may be produced by over-expressing the protein in microbes such as Escherichia coli. When using microbial proteins in a study for risk assessment, it is essential that their suitability as surrogates for the plant-produced transgenic proteins is established; that is, the proteins are equivalent for the purposes of the study. Equivalence does not imply that the plant and microbial proteins are identical, but that the microbial protein is sufficiently similar biochemically and functionally to the plant protein such that studies using the microbial protein provide reliable information for risk assessment of the transgenic crop. Equivalence is a judgement based on a weight of evidence from comparisons of relevant properties of the microbial and plant proteins, including activity, molecular weight, amino acid sequence, glycosylation and immuno-reactivity. We describe a typical set of methods used to compare proteins in regulatory risk assessments for transgenic crops, and discuss how risk assessors may use comparisons of proteins to judge equivalence.
机译:大多数商业转基因作物都经过基因工程改造以产生新的蛋白质。评估使用这些农作物对人类和动物健康以及对环境的风险的研究需要几克转基因蛋白。从农作物中产生足够的纯化的转基因蛋白通常非常困难。然而,可以通过在诸如大肠杆菌的微生物中过表达蛋白质来产生足够可接受纯度的充足蛋白质。在用于风险评估的研究中使用微生物蛋白时,必须确定其适合作为植物产生的转基因蛋白的替代物;也就是说,蛋白质对于研究目的是等效的。等价并不意味着植物蛋白和微生物蛋白是相同的,而是微生物蛋白在生物化学和功能上与植物蛋白足够相似,因此使用微生物蛋白进行的研究为转基因作物的风险评估提供了可靠的信息。等效性是根据微生物和植物蛋白相关特性(包括活性,分子量,氨基酸序列,糖基化和免疫反应性)的比较得出的证据权重作出的判断。我们描述了一组用于比较转基因作物监管风险评估中蛋白质的典型方法,并讨论了风险评估者如何使用蛋白质比较来判断等价性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号